Alessia Bari
Expertise in
6
conditions

Alessia Bari

Reggio Nell'emilia, IT 
Expertise in
6
conditions
Reggio Nell'emilia, IT 

Overview

Alessia Bari practices practicing medicine in Reggio Nell'emilia, Italy.

Ms. Bari is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, and Classical Hodgkin Lymphoma.

She is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Reggio Nell'emilia, Italy
Other Locations
Modena, Italy
Rimini, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: R2-MANT, R-MANT
Study Phase: Phase 3

41 Total Publications

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.
Journal: Blood advances
Published: October 14, 2025

Frequently Asked Questions about Alessia Bari

Is Alessia Bari a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alessia Bari is classified as an Distinguished expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alessia Bari participate in research or clinical trials?

Yes. Alessia Bari has published 41 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Alessia Bari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bari's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile